--- title: "Kernex Microsystems — Deep Dive Analysis" ticker: "KERNEX" date: "2026-10-20" tags: ["deep-dive","fundamental","railways","kavach","capital-goods","small-cap"] summary: "Kernex is the cheapest stock in the Kavach pack at 15x earnings, and on FY27 execution it may be cheaper still: Q1 revenue was Rs 504 Cr against Rs 431 Cr for all of FY26. But the order book fell 12% QoQ to Rs 3,641 Cr, receivables sit at 268 days, borrowings tripled, and HBL has guided that Kavach revenue peaks around FY28. Verdict: ACCUMULATE ON EXECUTION, NOT A SWING SETUP." model: "deepseek-v4-flash" watchlist: true priceAtAnalysis: 1737.6 support: 1712 resistance: 1817 supports: [1573, 1400] resistances: [1960, 2200] verdict: "ACCUMULATE ON EXECUTION — NOT A SWING SETUP" --- **Ticker:** KERNEX (NSE: KERNEX, BSE: 532686) **Sector:** Railways — safety and signalling electronics (Kavach/TCAS) **Price:** ₹1,737.60 (NSE close, 20 October 2026) **52W High / Low:** ₹2,580.00 / ₹850.00 **Analysis Date:** 20 October 2026 **Data Source:** Screener.in consolidated (Q1 FY27 quarterlies), TradingView NSE technicals, NSE corporate filings, CARE Ratings press release (12 October 2026), company investor presentation (4 September 2026), Q1 FY27 results coverage --- ## 1. Quick Snapshot | Metric | Value | |---|---| | **Current price** | ₹1,737.60 | | **Market cap** | ₹2,925 Cr | | **52-week range** | ₹850 – ₹2,580 | | **Distance from high / low** | -32.6% / +104% | | **Trailing P/E** | 15.3x | | **Price / book** | 11.7x (book value ₹148) | | **ROCE / ROE** | 47.8% / 43.5% | | **Q1 FY27 revenue (consolidated)** | ₹503.58 Cr (+800% YoY) | | **Q1 FY27 EBITDA / margin** | ₹162.82 Cr / 32.3% | | **Q1 FY27 PAT** | ₹109.85 Cr (+1,372% YoY) | | **Q1 FY27 EPS** | ₹65.37 | | **Order book (13 Aug 2026)** | ₹3,641 Cr incl. GST | | **Promoter holding** | 28.73% | | **Dividend** | None | | **1Y / 6M / 3M return** | +31.6% / +46.4% / -18.3% | **The one-paragraph version.** Kernex makes Kavach, India's indigenous train-collision-avoidance system, and it is one of only three suppliers with RDSO approval for Version 4.0. After six loss-making years waiting for that approval, the business has crossed into hyper-growth: one quarter of FY27 produced more revenue (₹504 Cr) than the whole of FY26 (₹431 Cr), at a 32% operating margin. The stock has de-rated 33% from its high anyway, because the order book fell 12% quarter-on-quarter as work was executed, receivables are 268 days, and the man who runs the larger listed peer has told shareholders that Kavach revenue will dip after FY28. At 15x trailing earnings — the cheapest in the railway pack — the argument is whether FY27's cash is enough to pay for the post-2028 hole. --- ## 2. What Kernex Actually Does Kernex Microsystems was incorporated in 1991 and has spent most of its listed life (since 2005) making railway safety electronics from a 10-acre, 265,000 sq ft campus at Hardware Park in Hyderabad. It is an ISO 9001-certified 100% export-oriented unit with roughly 740 staff across R&D, engineering, verification and validation, production and projects. Three product lines matter: - **Kavach / TCAS** (Train Collision Avoidance System) — both on-board locomotive equipment and trackside installation, including the station-level infrastructure - **Automatic block signalling and level-crossing control** — the older core business - **EPC works** for related railway infrastructure It is not a pure Kavach play. But Kavach is what the earnings now depend on, and the company's own investor material says so. Its earlier anti-collision device was discontinued in 2017 when Indian Railways moved to the TCAS standard, and the long product-approval cycle that followed is why revenue stayed near ₹1–9 Cr a quarter until FY24 and why the company lost money through FY22. **The structural point for valuation:** this is a single-customer business. Indian Railways production units — Chittaranjan Locomotive Works, Banaras Locomotive Works, Patiala Locomotive Works, the Integral Coach Factory — award the orders, set the specifications and pay the bills. There is no diversification story here, only an execution story. --- ## 3. The Kavach Inflection — Q1 FY27 The June 2026 quarter is the most important quarter in the company's history. | Metric (consolidated) | Q1 FY27 | Q1 FY26 | YoY | |---|---|---|---| | Sales | **₹503.58 Cr** | ₹56 Cr | **+800%** | | Operating profit | ₹162.82 Cr | ₹13 Cr | ~12x | | OPM | **32.3%** | 22% | +1,000 bps | | Interest | ₹13 Cr | ₹3 Cr | 4x | | PBT | ₹148 Cr | ₹10 Cr | ~15x | | Net profit | ₹109.85 Cr | ₹7 Cr | **+1,372%** | | EPS | ₹65.37 | ₹4.45 | — | For scale: FY26 consolidated revenue was ₹431 Cr and FY26 PAT was ₹88 Cr. **Q1 FY27 alone beat the entire prior year on both lines.** Standalone tells the same story — ₹502 Cr revenue, ₹163 Cr EBITDA, ₹148 Cr PBT, ₹110 Cr PAT, EPS ₹65.21 — which is expected, since the subsidiary (AGI, with offices in Egypt and the US) is small. The margin is the part that surprised the market. A 32.3% operating margin on a railway EPC contract is not normal for this sector, and it reflects a mix shift toward on-board locomotive kits rather than trackside civil work, plus the operating leverage of a fixed cost base that has been under-utilised for six years. **Two things inside the quarter that the headline ignores:** 1. **A ₹30.05 Cr warranty provision** was taken in Q1. That is roughly 18% of the quarter's operating profit, set aside against future Kavach warranty claims. Management took it voluntarily in a blow-out quarter, which is prudent, but it also signals that field reliability of the deployed base is not yet a closed question. 2. **The auditor's emphasis of matter.** Trade receivables of ₹4.23 Cr have been outstanding more than three years (with a ₹3.35 Cr expected-credit-loss provision against them), and bank guarantees of ₹2.65 Cr given to one customer are under arbitration. Small numbers against a ₹504 Cr quarter, but they are the kind of item that should be read alongside the 268-day receivable figure in section 7. --- ## 4. The Order Book: Big, Shrinking, and 2028-Shaped This is where the bear case lives, and it is arithmetic rather than opinion. | Date | Order book (incl. GST) | |---|---| | 29 May 2026 | ₹4,150 Cr | | 13 Aug 2026 (Q1 FY27) | **₹3,641 Cr** | | Change | **-₹509 Cr (-12%)** | The company has won ₹5,174 Cr of orders in total and executed ₹1,687 Cr, leaving the ₹3,487 Cr balance shown in its September presentation. A further ₹2,100 Cr of that is scheduled for FY27 execution — **4.9x FY26 revenue** — which is why the growth is not in doubt for the next four quarters. But a shrinking order book during a quarter when revenue multiplied eightfold is a signal, not a glitch. Three things explain it: - **Execution is running ahead of intake.** That is a good problem in the short term and a bad one in the medium term. - **The big orders are already won.** The CLW contract for 3,024 locomotives was awarded in December 2024 at ₹2,041 Cr, and the largest incremental wins since have been small — ₹475 Cr in May 2026, ₹66.62 Cr from ICF in August 2026. - **The tender pipeline is not converting at the rate the market assumed.** Kavach is being rolled out across roughly 12,000 remaining locomotives, but awards are lumpy and competitive, and the three approved vendors bid against each other. **The 2028 question.** HBL Engineering — the largest listed Kavach supplier, and the closest comparable — has told its own shareholders that Kavach sales should be steady at ₹1,300–1,500 Cr a year through FY26-FY28 and then **dip**. Its FY25 annual report says so explicitly, and its management repeated it at the 2025 AGM. Kernex has not given a similar warning, but it sells into the same programme, to the same customer, on the same equipment cycle. If HBL's read is right, Kernex's FY27-FY28 earnings are a peak, not a base. That is precisely why a stock growing at 800% trades at 15x. --- ## 5. Execution: The CLW Clock The CLW order is the ballgame: 3,024 locomotives, of which **1,360 units (45%) had been supplied as of 13 August 2026**, with 175 ready for dispatch and 1,025 "almost completed". The company guides the remaining dispatches to be finished by **November 2026**, with installation continuing into **February 2027**. Three implications: - **Q2 and Q3 FY27 will carry the bulk of the remaining CLW revenue.** If dispatch completes by November, the revenue recognition tail runs into Q4 and the installation revenue into Q1 FY28. - **The FY27 revenue number is therefore front-loaded and knowable.** ₹2,100 Cr of in-hand FY27 order book against a company that has just demonstrated ₹504 Cr in a quarter is not a stretch — it is roughly four more quarters like Q1. - **What happens after February 2027 is the open question.** With ₹3,641 Cr of order book and ₹1,541 Cr of it beyond FY27, the company needs fresh awards in FY27-FY28 to keep the run-rate alive. That is what the market is watching, and it is why the stock fell on a quarter that beat everything. One more asset worth noting: every locomotive fitted generates an **annual maintenance contract** — the company's own framing is roughly 3% of contract value a year for 11 years. On 3,024 locomotives that is a meaningful annuity layer, but it starts small and compounds slowly; it will not fill a post-2028 hole on its own. --- ## 6. Margins, Warranty, and Earnings Quality The 32.3% operating margin invites the obvious question: is it real, and does it last? Evidence for: - The mix has shifted to on-board kits, which carry more software and less civil work - Fixed costs (740 staff, 265,000 sq ft, in-house test labs) are now spread over 8x the revenue - The company has pricing power in the short term because only three vendors are approved and demand is mandated Evidence against: - The ₹30 Cr warranty provision is a direct charge against future margin - Railway EPC pricing is tender-driven; the next round of awards will be bid against two competitors who can see the same margin - The CARE report flags "execution and technology risk" and the "tender-based nature of business" as rating constraints, not footnotes **The earnings-quality note:** Q1's PAT of ₹110 Cr was earned with ₹13 Cr of interest cost, up from ₹3 Cr a year earlier. That is the cost of financing a working-capital-heavy model. Profit is real, but it is being funded by debt, and the debt is growing faster than equity. --- ## 7. Cash: 268 Receivable Days and a Tripled Borrowing Line This is the least comfortable part of the story, and it is why the P/E of 15 should not be taken at face value. | Balance sheet item (consolidated) | Mar 2025 | Mar 2026 | |---|---|---| | Borrowings | ₹40 Cr | **₹162 Cr** | | Other liabilities | ₹38 Cr | **₹509 Cr** | | Total assets | ₹236 Cr | **₹919 Cr** | | Reserves | ₹141 Cr | ₹231 Cr | **Receivable days: 268.** For a business selling to Indian Railways, long receivables are normal — but 268 days means three-quarters of a year of revenue is sitting in the working-capital cycle. Against FY26 revenue of ₹431 Cr, that is roughly ₹316 Cr tied up. The company has sanctioned working-capital limits of ₹490 Cr, with ₹281 Cr undrawn and a further ₹165 Cr under enhancement. **Why it matters for the equity:** a business that earns ₹110 Cr in a quarter but needs ₹300+ Cr of working capital to do it is not self-funding at this growth rate. Every incremental rupee of revenue consumes cash before it produces it. That is sustainable while Indian Railways pays and the banks renew limits — the CARE upgrade says they will — but it caps how much of the profit can ever reach shareholders, and it is the reason there is no dividend. **The cash-conversion test to watch in Q2:** operating cash flow against PAT. If Q2 shows ₹100+ Cr of profit and negative operating cash flow, the model is consuming capital faster than it earns it. --- ## 8. The Balance Sheet and the CARE Upgrade On **12 October 2026**, CARE Ratings upgraded Kernex: | Facility | Amount | Rating | Action | |---|---|---|---| | Long-term / short-term bank facilities | ₹125 Cr (from ₹100 Cr) | CARE BBB; Stable / CARE A3+ | Upgraded from BBB- / A3 | | Long-term bank facilities | ₹10 Cr | CARE BBB; Stable | Assigned | | Long-term bank facilities | ₹525 Cr (from ₹175 Cr) | CARE BBB; Stable | Upgraded from BBB- | Two things in that table matter more than the rating itself. First, **the rated facilities were tripled** — ₹175 Cr to ₹525 Cr — which is the bank's acknowledgement that the working-capital requirement has structurally changed, not temporarily spiked. Second, CARE's negative sensitivities are explicit: **working capital cycle beyond 150 days**, or **revenue/profit declining more than 30%**. The company is currently at 268 receivable days, well past the first threshold, and the second is the FY28 risk in rating-agency language. Being one notch above investment grade with a stable outlook is a fair description of this business today: credible, growing, and dependent on a single customer's payment cycle. --- ## 9. Ownership: A 28.7% Promoter Stake | Holder | Sep 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |---|---|---|---|---| | Promoters | 28.97% | 28.85% | 28.73% | **28.73%** | | FIIs | 0.54% | 0.30% | 2.48% | **1.19%** | | DIIs | 0.39% | 0.02% | 0.05% | **0.05%** | | Public and others | ~70% | ~71% | ~69% | ~70% | A 28.7% promoter stake is low for an Indian small-cap and it has drifted down slowly for three years (29.14% in December 2023). It is above the 25% minimum for a promoter to retain control, but not by much, and there is no large strategic holder behind it. Domestic institutions own effectively nothing — 0.05% DII — so the price is set by retail and a small number of foreign funds. The positive read: FIIs went from 0.30% in March to 2.48% in June before settling at 1.19% in September, so there is some institutional interest. The negative read: with a 1.68 crore share count and ₹31 Cr of average daily turnover, a single fund changing its mind moves the stock. **No pledge is reported**, which matters given the low promoter holding. --- ## 10. Valuation: 15x Against a 23–45x Pack | Company | P/E (TTM) | Market cap | 1Y return | 3M return | |---|---|---|---|---| | **Kernex** | **15.3x** | ₹2,925 Cr | +31.6% | -18.3% | | HBL Engineering | 28.9x | ₹22,507 Cr | -11.6% | +11.2% | | RailTel | 23.2x | ₹8,025 Cr | -32.5% | -15.2% | | IRCON | 18.7x | ₹9,800 Cr | -39.5% | -19.6% | | RVNL | 45.1x | ₹40,554 Cr | -41.9% | -13.9% | Kernex is the cheapest in the pack on trailing earnings, and by a wide margin. It is also the only one whose earnings are growing rather than shrinking, and the only one that has outperformed over twelve months (+31.6% against HBL's -11.6% and RVNL's -41.9%). **The forward arithmetic is where it gets interesting.** If FY27 delivers ₹2,100 Cr of the in-hand order book at a 25-30% operating margin and a 20% net margin, FY27 PAT could land between ₹400 Cr and ₹500 Cr — a forward P/E of **6x to 7x**. Even at a 15% net margin and ₹1,800 Cr revenue, PAT of ₹270 Cr gives 11x. That is either the cheapest growth stock in Indian railways, or the market is correctly pricing a one-off year. The difference between those two readings is the FY28 order book, and nobody — including the company — has shown it yet. **On book value it is not cheap.** At 11.7x book, the balance sheet is not providing any support; the valuation rests entirely on earnings and the durability of the Kavach cycle. --- ## 11. What the Market Is Pricing The stock's three-month performance (-18.3%) against its six-month (+46.4%) tells the story: the market re-rated it into the Q1 result and then de-rated it out of it, despite the numbers. Three things did that: 1. **Order book degrowth (-12% QoQ)** on a quarter that otherwise beat everything. 2. **HBL's explicit guidance** that Kavach revenue peaks around FY28 and dips thereafter — read across to the smaller, more concentrated player. 3. **The warranty provision**, which says the installed base is not yet fully proven in the field. None of those is a governance event. All three are about the durability of the earnings, which is exactly what a 15x multiple is debating. --- ## 12. Risks - **Customer concentration.** Indian Railways production units are effectively the entire customer base. - **Post-FY28 cliff.** If Kavach ordering peaks, revenue normalises sharply and the trailing P/E of 15 becomes a forward P/E of 15 on a shrinking base. - **Working capital.** 268 receivable days, ₹162 Cr of borrowings and ₹509 Cr of other liabilities. Growth consumes cash. - **Execution risk.** The CLW installation tail runs to February 2027; slippage moves revenue between quarters and can trigger penalties. - **Low promoter holding (28.73%).** No controlling bloc, no pledge, but limited skin in the game relative to peers. - **Thin liquidity.** ₹31 Cr average daily turnover and a 1.68 crore share count; exits are harder than entries. - **Competition.** Three approved vendors bidding for the same tenders; the 32% margin is not protected by a moat, only by an approval. - **Warranty.** ₹30 Cr provisioned in one quarter; if field failures rise, so does the provision. --- ## 13. Technical Analysis ### 13.1 Indicator panel (20 October 2026, CMP ₹1,737.60) | Indicator | Value | Reading | |---|---|---| | RSI (14) | 48.4 | Neutral — no momentum either way | | SMA 20 | ₹1,730 | Price **0.4% above** — barely | | SMA 50 | ₹1,817 | Price **4.4% below** | | SMA 100 | ₹1,960 | Price **11.3% below** | | SMA 200 | ₹1,573 | Price **10.5% above** — primary trend intact | | ATR (14) | ₹85.5 | 4.9% a day — wide | | 52-week high / low | ₹2,580 / ₹850 | -32.6% from high, +104% above low | | Volume | 1.21 lakh vs 1.78 lakh 30-day average | **0.68x — thin** | | 1Y / 6M / 3M | +31.6% / +46.4% / **-18.3%** | Strong year, weak quarter | **Structure:** the stock topped at ₹2,580, fell to ₹1,400 in the summer, bounced to ₹2,100, and has been making lower highs since — now at ₹1,737, below the 50- and 100-day averages but above the 200-day. This is a corrective downtrend inside a longer uptrend, not a base. There is no consolidation tight enough to call a setup, and the 20-day average is flat. **Interpretation:** the tape is neutral-to-weak. The stock is holding the 200-DMA, which is the line that separates "correction" from "trend break", but it has lost the 50- and 100-day averages and volume is drying up. For a position buyer that is acceptable. For a swing trader it is not: there is no breakout, no tight base, and no volume expansion. --- ## 14. All 25 Points Assessed | # | Point | Assessment | Verdict | |---|---|---|---| | 1 | Price position (within 25% of high) | 32.6% below the 52-week high of ₹2,580 | Fail | | 2 | Clear uptrend | Lower highs since ₹2,100; below 50/100-DMA, above 200-DMA | Caution | | 3 | Volume characteristics | 0.68x the 30-day average — no expansion | Caution | | 4 | Clean price action | -18.3% in three months, 4.9% daily ATR | Caution | | 5 | EMA alignment (9>20>50>200) | Price below EMA20 (₹1,744) and EMA50 (₹1,805); alignment broken | Fail | | 6 | Chart pattern / base | No base — corrective downtrend from ₹2,580 | Caution | | 7 | Base quality | No consolidation to assess; not a tight base | Fail | | 8 | ADR suitable | ATR ₹85.5, about 4.9% a day — wide but tradeable | Pass | | 9 | Primary uptrend | Yes — 10.5% above the 200-DMA, +31.6% over a year | Pass | | 10 | Follow one trading model | Discipline point | Pass | | 11 | Sector strength | Railway capex strong, but the listed pack is down (RVNL -42%, RailTel -33% over a year) | Caution | | 12 | Tailwind | Kavach mandate, ~12,000 locomotives still to be fitted | Pass | | 13 | IPO consideration | Not applicable — listed since 2005 | N/A | | 14 | Price action strength vs peers | +31.6% over a year against HBL's -11.6% and RVNL's -41.9% | Pass | | 15 | Sector & government boost | Kavach rollout, railway capex, Make-in-India | Pass | | 16 | Fundamental quality | ROCE 47.8%, ROE 43.5%, but 268 receivable days and a 28.7% promoter stake | Caution | | 17 | Quarterly earnings growth | Revenue +800%, PAT +1,372% in Q1 FY27 | Pass | | 18 | Delivery percentage | **Not retrieved** — the NSE archive rate-limited every request during this analysis; volume only | Caution | | 19 | News & institutional activity | CARE upgrade on 12 Oct, FIIs up to 1.19%, but order book -12% and a ₹30 Cr warranty provision | Caution | | 20 | Risk management | Definable: ₹1,712 (20 Oct low), then ₹1,573 (200-DMA); a weekly close below ₹1,573 invalidates | Pass | | 21 | Market environment | Nifty in a downtrend; small-caps under pressure | Caution | | 22 | Liquidity | ₹31 Cr average daily turnover, 1.68 Cr shares — thin for size | Caution | | 23 | Relative strength | Outperforming the benchmark over one year | Pass | | 24 | Breakout confirmation | None — price is below the 50- and 100-DMA with no base | Fail | | 25 | Trading psychology | Patience is available; no FOMO either way | Pass | **Score: 15.0 / 25** (one item N/A; rule: Pass = 1, Caution = 0.5, Fail = 0, N/A excluded — 10 Pass, 10 Caution, 4 Fail). That is **below the 17-point threshold**, with critical fails on items 1, 5, 7 and 24. On the checklist's own rules this is not a swing setup. The distinction matters: the fundamentals are cheap, but the chart is broken, and the two should not be confused. --- ## 15. Levels and Verdict ### 15.1 Levels | Level | Price | Basis | |---|---|---| | Resistance 3 | ₹2,580 | 52-week high | | Resistance 2 | ₹2,100 | August 2026 swing high | | **Resistance 1 (primary)** | **₹1,817** | 50-DMA | | **CMP** | **₹1,737.60** | 20 October 2026 | | **Support 1** | **₹1,712** | 20 October 2026 low | | **Support 2 (primary)** | **₹1,573** | 200-DMA — the line that matters | | Support 3 | ₹1,400 | Summer 2026 low | | Invalidation | Weekly close below ₹1,550 | Primary trend break | ### 15.2 Verdict **ACCUMULATE ON EXECUTION — NOT A SWING SETUP.** Three reasons the fundamentals justify a position: 1. **The earnings are real and the multiple is low.** 15.3x trailing, and on FY27 in-hand order book the forward multiple could be 6-11x. No other Kavach name is close. 2. **The CLW order gives FY27 visibility.** ₹2,100 Cr of in-hand FY27 work against ₹431 Cr of FY26 revenue; 45% of the locomotive order is already supplied. 3. **The credit rating improved, not deteriorated** — BBB with a stable outlook on triple the facility size, on 12 October. Three reasons not to treat it as a trade: 1. **The order book is shrinking** (-12% QoQ) and the pipeline is not converting fast enough to offset execution. 2. **FY28 is an open question** — HBL's own guidance says Kavach revenue peaks and then dips. 3. **The chart is broken** — 15.0/25 on the checklist, below the 50- and 100-DMA, no base. ### 15.3 What I would do | Investor profile | Action | |---|---| | Long-term, 2-3 year horizon | **Accumulate in two tranches**: 50% at ₹1,700-1,750, 50% at ₹1,570-1,620 near the 200-DMA. Size at 2-3% of portfolio — the concentration and liquidity risks do not justify more | | Existing holder | **Hold.** The thesis (cheap FY27 earnings, execution on track) is intact; the ₹1,573 level is the risk marker. Trim into strength above ₹2,100 only if the order book has not stabilised | | Swing trader | **No trade.** 15/25, no base, no breakout, thin volume. Wait for a close above ₹1,817 on volume before considering it | | Value investor | **Not a value stock.** 11.7x book, no dividend, single customer, 268 receivable days. This is a growth-at-a-low-multiple trade, not a margin-of-safety investment | **The honest tension:** the cheapest stock in the pack is cheap because the market has decided the earnings peak in FY28. If the order book stabilises at ₹3,500 Cr+ through the next two quarters, that conclusion is wrong and the stock re-rates. If it keeps falling, the 15x is a fair price for a declining business. --- ## 16. Catalysts to Watch | Event | Timing | Why it matters | |---|---|---| | **Q2 FY27 results** | November 2026 | Confirms the CLW revenue run-rate and, critically, whether operating cash flow turned positive | | CLW dispatch completion | November 2026 | 1,025 units nearly complete; slippage would move revenue into Q3 | | **New Kavach awards** | FY27-FY28 | The single most important variable: does the ₹3,641 Cr order book stabilise or keep shrinking? | | Installation completion | February 2027 | Ends the CLW tail and starts the AMC annuity | | Working capital cycle | Next two quarters | CARE's own negative trigger is beyond 150 days; the company is at 268 receivable days | | Post-FY28 Kavach ordering | FY27-FY28 | HBL's guidance is the read-across; any Indian Railways indication of the FY28 order size is the swing factor | | Rating outlook | Next review | BBB stable; a further upgrade would lower the funding cost that currently eats ₹13 Cr a quarter | --- ## 17. What Would Change My Mind **To the upside:** - A fresh order book above ₹4,000 Cr in Q2 or Q3 FY27, which would break the "peak cycle" thesis - Positive operating cash flow in Q2 despite growth, which would show the working-capital model is manageable - A large Kavach award for the remaining ~12,000 locomotives being split rather than contested **To the downside:** - A second consecutive quarter of order book decline - Receivable days above 300, or a further jump in borrowings - Any warranty provision materially above the ₹30 Cr taken in Q1 - A revenue or profit decline of more than 30% — CARE's own downgrade trigger --- ## 18. Disclaimer & Sources This analysis is for information and education only. It is not investment advice and not a recommendation to buy, sell or hold. It was prepared by an AI agent (deepseek-v4-flash via Hermes Agent) from public sources. Verify all figures against company filings before acting. **Sources** - Screener.in consolidated page for KERNEX (20 October 2026) — Q1 FY27 quarterlies (revenue ₹503.58 Cr, OPM 32%, PAT ₹109.85 Cr, EPS ₹65.37), FY26 annuals, balance sheet through March 2026, shareholding through September 2026, ROCE 47.8%, ROE 43.5%, book value ₹148 - TradingView scanner for NSE:KERNEX (20 October 2026) — price ₹1,737.60, RSI(14) 48.4, SMA 20/50/100/200 at ₹1,730/₹1,817/₹1,960/₹1,573, ATR ₹85.5, 52-week range ₹850–₹2,580, peer multiples for HBL, RailTel, IRCON and RVNL - CARE Ratings press release, 12 October 2026 — upgrade to CARE BBB; Stable / CARE A3+, facility enhancement from ₹175 Cr to ₹525 Cr, rationale and negative sensitivities - Kernex investor presentation filed 4 September 2026 (NSE) — standalone Q1 FY27 revenue ₹502 Cr, EBITDA ₹163 Cr, PAT ₹110 Cr, balance order book ₹3,487 Cr including GST, working-capital limits ₹490 Cr with ₹281 Cr undrawn - NSE corporate filings, July-October 2026 — commissioning of Kavach on 207 route-km of North Central Railway (2 July), Q1 results (13 August), executive and independent director appointments, credit rating revision (13 October) - Q1 FY27 results coverage (ScanX, Sahi Markets, Kalkine, Arthneeti) — order book ₹3,641 Cr as of 13 August, CLW 45% supplied, ₹30.05 Cr warranty provision, auditor's emphasis of matter on ₹4.23 Cr receivables and ₹2.65 Cr bank guarantees under arbitration - HBL Engineering disclosures and AGM commentary (FY25 annual report, 39th AGM September 2025) — Kavach revenue guidance of ₹1,300–1,500 Cr a year through FY28, then a decline **Data limitations:** NSE bhavcopy delivery percentages could not be retrieved for this analysis — the NSE archive returned a bot-wall response to every request on 20 October, so item 18 of the checklist is marked Caution rather than scored. Delivery should be checked before acting. The FY27 forward earnings range is derived from the company's own ₹2,100 Cr in-hand order book and is sensitive to the revenue-recognition schedule; it is an estimate, not guidance.